Gilbert O Fruhwirth
Overview
Explore the profile of Gilbert O Fruhwirth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maiques O, Sallan M, Laddach R, Pandya P, Varela A, Crosas-Molist E, et al.
Nat Commun
. 2025 Feb;
16(1):1394.
PMID: 39952917
The extracellular matrix (ECM) controls tumour dissemination. We characterise ECM organization in human and mouse tumours, identifying three regions: tumour body, proximal invasive front and distal invasive front. Invasive areas...
2.
Palhares L, Grandits M, Stoker K, Chauhan J, Sow H, Fruhwirth G, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):49.
PMID: 39934835
Background: Tumor-targeting IgE antibodies have elicited potent tumor-restricting effects by recruiting immune effector mechanisms. However, a dedicated platform for the generation, selection and evaluation of novel IgEs based on target...
3.
Ashmore-Harris C, Ayabe H, Yoshizawa E, Arisawa T, Takada Y, Takebe T, et al.
Mol Ther Methods Clin Dev
. 2025 Feb;
33(1):101406.
PMID: 39927149
Human induced pluripotent stem cell (hiPSC)-derived liver cell therapies such as hepatocyte-like cells and liver organoids could provide unlimited therapeutic cells for clinical transplantation, but an inadequate understanding of their...
4.
Costa I, Firth G, Kim J, Banu A, Pham T, Sunassee K, et al.
Int J Radiat Oncol Biol Phys
. 2024 May;
120(4):1124-1134.
PMID: 38797497
Purpose: Despite a rise in clinical use of radiopharmaceutical therapies, the biological effects of radionuclides and their relationship with absorbed radiation dose are poorly understood. Here, we set out to...
5.
Iyer R, Needham S, Galdadas I, Davis B, Roberts S, Man R, et al.
Nat Commun
. 2024 Mar;
15(1):2130.
PMID: 38503739
The Epidermal Growth Factor Receptor (EGFR) is frequently found to be mutated in non-small cell lung cancer. Oncogenic EGFR has been successfully targeted by tyrosine kinase inhibitors, but acquired drug...
6.
Man R, Qiu Y, Leung S, Fruhwirth G, Lam J
Eur J Pharm Biopharm
. 2024 Jan;
195:114177.
PMID: 38185193
Background: Small interfering RNA (siRNA) holds great promise for treating various lung diseases, but the lack of safe and efficient pulmonary siRNA delivery systems has hindered its advance into the...
7.
Grimsdell B, Saleem A, Volpe A, Fruhwirth G
Methods Mol Biol
. 2023 Nov;
2729:303-330.
PMID: 38006504
Noninvasive long-term imaging of therapeutic cells in preclinical models can be achieved through introducing a reporter gene into the cells of interest. Despite important recent developments such as gene editing,...
8.
Cawthorne C, Volpe A, Fruhwirth G
Methods Mol Biol
. 2023 Nov;
2729:195-220.
PMID: 38006498
Positron emission tomography (PET) has transformed medical imaging, and while first developed and applied to the human setting, it has found widespread application at the preclinical level over the past...
9.
Read M, Brookes K, Zha L, Manivannan S, Kim J, Kocbiyik M, et al.
Clin Cancer Res
. 2023 Nov;
30(7):1352-1366.
PMID: 37921808
Purpose: Patients with aggressive thyroid cancer are frequently failed by the central therapy of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of the sodium/iodide symporter (NIS)....
10.
Skourti E, Volpe A, Lang C, Johnson P, Panagaki F, Fruhwirth G
Front Immunol
. 2023 Jun;
14:1180233.
PMID: 37359535
Introduction: MicroRNAs are small non-coding RNAs and represent key players in physiology and disease. Aberrant microRNA expression is central to the development and progression of cancer, with various microRNAs proposed...